Welcome, Guest. Please login or register.
May 18, 2024, 12:45:06 am

Login with username, password and session length

  • Total Posts: 773516
  • Total Topics: 66380
  • Online Today: 240
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 0
Guests: 199
Total: 199


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Viral suppression with anti-HIV-1 antibody - Phase 1b 3BNC117 & 10-1074  (Read 4985 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,483
  • Threads: @jim16309
    • Social Media: Threads
Phase 1b study of the safety, tolerability and anti-viral activity of the combination of two broad and potent anti-HIV-1 antibodies, 3BNC117 and 10-1074

April 13th 2022

In Full: https://doi.org/10.1038/s41586-022-04597-1 Gaebler, C., Nogueira, L., Stoffel, E. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature (2022).

In Brief:

Study eligibility criteria included ongoing ART and viral suppression with plasma HIV-1 RNA levels of less than 50 copies per ml for at least 12 months (with one blip of fewer than 500 copies per ml allowed), fewer than 20 copies per ml at screening, and CD4+ T cell counts above 500 cells

Participants in the treatment groups received up to seven infusions of 30 mg kg−1 of each antibody over the course of 20 weeks at 2-week (infusions 1–3) and 4-week intervals

26 enrolled participants were randomized to group 1 and eight were randomized to group 2

Participants in group 1 were asked to discontinue their ART 2 days after the first 3BNC117 and 10-1074 infusions, whereas participants in group 2 remained on ART before discontinuing the antiretrovirals after 26 weeks

Thirteen out of seventeen (76%) evaluable group 1 participants maintained viral suppression for at least 20 weeks after ART discontinuation

The participants in group 2 maintained viral suppression for a median of 7 weeks (4–9 weeks) after ART was discontinued 13 weeks (range 10–15 weeks) after the last bNAb infusion.

There was no statistically significant difference in time to viral rebound after ART interruption between group 1 and group 2 participants

We conclude that repeated infusions of two anti-HIV-1 bNAbs can maintain viral suppression for longer periods of time than previously reported as long as bNAb levels remain therapeutic. Similar results were observed in a parallel placebo-controlled clinical trial—sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIAID/NIH)—in which people living with HIV who started ART during the early phase of infection received eight doses of the same antibody combination over a 24-week period in the absence of ART

Past coverage of 3BNC117 & 10-1074


2015 - new antibody therapy shows promise in suppressing HIV infection

2016 - HIV Antibody 3BNC117 Delays Viral Rebound


2017 - Antibody (10-1074) trial in PLHIV.

HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram


Terms of Membership for these forums

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.